RGEN

Repligen Corporation
$181.38+$8.43+4.87%Price as of Nov 3, 2026, 9:30 AM ET

Key stats

Market cap
11.5B
Open
—
Day range
—
52-week range
$100.99 – $198.87
Volume
5.09K
Avg volume
1.47M

Earnings

Q3 FY26Beat
Expected$0.47
Actual$0.53
Q2 FY26
Actual$0.09
Q1 FY26
Actual$0.15
Q4 FY25
Actual$0.23

Next earnings call Feb 18, 2027

About

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.

Employees
2,000
Headquarters
Waltham, MA